Evaluation of metaphylactic RNA interference to prevent equine herpesvirus type 1 infection in experimental herpesvirus myeloencephalopathy in horses.
暂无分享,去创建一个
[1] G. R. Van de Walle,et al. Equine alphaherpesviruses (EHV-1 and EHV-4) differ in their efficiency to infect mononuclear cells during early steps of infection in nasal mucosal explants. , 2011, Veterinary microbiology.
[2] A. Quintana,et al. Immunological characterization of the equine airway epithelium and of a primary equine airway epithelial cell culture model. , 2011, Veterinary immunology and immunopathology.
[3] Young Jik Kwon,et al. Efficient and targeted delivery of siRNA in vivo , 2010, The FEBS journal.
[4] E. Hodžić,et al. Use of quantitative real-time PCR for the detection of Salmonella spp. in fecal samples from horses at a veterinary teaching hospital. , 2010, Veterinary journal.
[5] P. Rottier,et al. Experimental infection with neuropathogenic equid herpesvirus type 1 (EHV-1) in adult horses. , 2010, Veterinary journal.
[6] L. Duchateau,et al. Replication kinetics of neurovirulent versus non-neurovirulent equine herpesvirus type 1 strains in equine nasal mucosal explants. , 2010, The Journal of general virology.
[7] S. Hussey,et al. Control of EHV-1 viremia and nasal shedding by commercial vaccines. , 2010, Vaccine.
[8] Rob Lambkin-Williams,et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.
[9] H. Erb,et al. The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses , 2009, Virus Research.
[10] G. R. Van de Walle,et al. A single-nucleotide polymorphism in a herpesvirus DNA polymerase is sufficient to cause lethal neurological disease. , 2009, The Journal of infectious diseases.
[11] K. Osterrieder,et al. Equine herpesvirus-1 consensus statement. , 2009, Journal of veterinary internal medicine.
[12] Nikolaus Osterrieder,et al. Effective Treatment of Respiratory Alphaherpesvirus Infection Using RNA Interference , 2009, PloS one.
[13] G. Allen. Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses. , 2008, American journal of veterinary research.
[14] R. S. Erkert,et al. Pharmacokinetics of valacyclovir in the adult horse. , 2008, Journal of veterinary pharmacology and therapeutics.
[15] C. Carter,et al. Prevalence of latent, neuropathogenic equine herpesvirus-1 in the Thoroughbred broodmare population of central Kentucky. , 2008, Equine veterinary journal.
[16] G. Palù,et al. A Point Mutation in a Herpesvirus Polymerase Determines Neuropathogenicity , 2007, PLoS pathogens.
[17] H. Nauwynck,et al. Pharmacokinetics of Acyclovir after Intravenous Infusion of Acyclovir and after Oral Administration of Acyclovir and Its Prodrug Valacyclovir in Healthy Adult Horses , 2007, Antimicrobial Agents and Chemotherapy.
[18] H. Nauwynck,et al. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. , 2007, Veterinary microbiology.
[19] G. Allen,et al. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. , 2007, Journal of veterinary internal medicine.
[20] G. Allen,et al. Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1. , 2010, Equine veterinary journal.
[21] W. D. Wilson,et al. Cytokine gene signatures in neural tissue of horses with equine protozoal myeloencephalitis or equine herpes type 1 myeloencephalopathy , 2006, Veterinary Record.
[22] J. Kydd,et al. The equine immune response to equine herpesvirus-1: the virus and its vaccines. , 2006, Veterinary immunology and immunopathology.
[23] C. Clarke,et al. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. , 2006, Journal of veterinary internal medicine.
[24] C. van Maanen,et al. Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). , 2006, Journal of veterinary internal medicine.
[25] N. Osterrieder,et al. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). , 2006, Vaccine.
[26] R. Bowden,et al. Analysis of Equid Herpesvirus 1 Strain Variation Reveals a Point Mutation of the DNA Polymerase Strongly Associated with Neuropathogenic versus Nonneuropathogenic Disease Outbreaks , 2006, Journal of Virology.
[27] N. Zhong,et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.
[28] S. Barik,et al. Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.
[29] N. Edington,et al. The role of endothelial cell infection in the endometrium, placenta and foetus of equid herpesvirus 1 (EHV-1) abortions. , 1991, Journal of comparative pathology.
[30] G. Dickinson,et al. An outbreak of paresis in mares and geldings associated with equid herpesvirus 1 , 1981, Veterinary Record.